Corresponding Author: Carlos Blanco, MD, PhD, Division of Epidemiology, Services and Prevention Research, National Institute on Drug Abuse, 6001 Executive Blvd, Bethesda, MD 20852 (firstname.lastname@example.org).
Published Online: September 1, 2020. doi:10.1001/jamapsychiatry.2020.3177
Conflict of Interest Disclosures: Dr Compton reports long-term stock holdings from General Electric, 3M Company, and Pfizer outside the submitted work. No other disclosures were reported.
Disclaimer: The views and opinions expressed in this report are those of the authors and should not be construed to represent the views of the National Institute on Drug Abuse, the National Institutes of Health, or any US government agency.
CA . Geographic disparities affect access to buprenorphine services for opioid use disorder. US Department of Health and Human Services Office of Inspector General. Published January 2020. Accessed June 14, 2020. https://oig.hhs.gov/oei/reports/oei-12-17-00240.pdf